{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:14:51Z","timestamp":1772781291620,"version":"3.50.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Crohn's and Colitis"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.crohns.2009.11.010","type":"journal-article","created":{"date-parts":[[2009,12,11]],"date-time":"2009-12-11T10:14:56Z","timestamp":1260526496000},"page":"275-282","source":"Crossref","is-referenced-by-count":21,"title":["A comparison of physician-rated disease severity and patient reported outcomes in mild to moderately active ulcerative colitis"],"prefix":"10.1093","volume":"4","author":[{"given":"Chris D.","family":"Poole","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark P.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandy Kildegaard","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig J.","family":"Currie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Marteau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"10.1016\/j.crohns.2009.11.010_bib1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.crohns.2008.10.004","article-title":"An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial","volume":"3","author":"Connolly","year":"2009","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.crohns.2009.11.010_bib2","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.crohns.2009.02.005","article-title":"An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis based on results from randomised controlled trial","volume":"3","author":"Connolly","year":"2009","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.crohns.2009.11.010_bib3","series-title":"World Health Organization, on behalf of the European Observatory on Health Systems and Policies","article-title":"Ensuring value for money in health care: the role of health technology assessment in the European Union","author":"Sorenson","year":"2008"},{"key":"10.1016\/j.crohns.2009.11.010_bib4","series-title":"Economic evaluation in health care: merging theory with practice","author":"Drummond","year":"2001"},{"key":"10.1016\/j.crohns.2009.11.010_bib5","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1136\/gut.2004.041616","article-title":"Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study","volume":"53","author":"Bassi","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2009.11.010_bib6","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1111\/j.1572-0241.1998.00537.x","article-title":"Health-related quality of life in Swedish patients with ulcerative colitis","volume":"93","author":"Hjortswang","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.11.010_bib7","unstructured":"NICE technology appraisal TA140. Evidence Review Group Report commissioned by the NHS R&D HTA Programme on behalf of NICE. Infliximab for ulcerative colitis (2007). (Accessed 16 August 2009: http:\/\/www.nice.org.uk\/nicemedia\/pdf\/UlcerativeColitisEvidenceReviewGroupReport.pdf)."},{"key":"10.1016\/j.crohns.2009.11.010_bib8","series-title":"Guide to the methods of technology appraisal (reference N0515)","author":"National Institute for Health and Clinical Excellence (NICE)","year":"2004"},{"key":"10.1016\/j.crohns.2009.11.010_bib9","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.gastro.2006.12.038","article-title":"A review of activity indices and efficacy points for clinical trials of medical therapy in adults with ulcerative colitis","volume":"132","author":"D'Haens","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.11.010_bib10","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/0016-5085(87)90621-4","article-title":"5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis","volume":"92","author":"Sutherland","year":"1987","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.11.010_bib11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/0272989X07309642","article-title":"Comparing the incomparable? A systematic review of competing techniques for converting descriptive measures of health status into QALY-weights","volume":"28","author":"Mortimer","year":"2008","journal-title":"Med Decis Making"},{"key":"10.1016\/j.crohns.2009.11.010_bib12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1572-0241.2005.40641.x","article-title":"Is endoscopy necessary for the measurement of disease activity in ulcerative colitis","volume":"100","author":"Higgins","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.11.010_bib13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1745-6215-8-17","article-title":"Outcome measurement in clinical trials for ulcerative colitis: towards standardization","volume":"8","author":"Cooney","year":"2007","journal-title":"Trials"},{"key":"10.1016\/j.crohns.2009.11.010_bib14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2014a new facility for the measurement of health-related quality of life","volume":"16","year":"1990","journal-title":"Health Policy"},{"key":"10.1016\/j.crohns.2009.11.010_bib15","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/gut.2004.060103","article-title":"Combined oral and enema treatment with pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild\/moderate active ulcerative colitis: a randomized, double blind, placebo controlled study","volume":"54","author":"Marteau","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2009.11.010_bib16","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.cgh.2009.04.004","article-title":"Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis","volume":"7","author":"Dignass","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2009.11.010_bib17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/0272989X05284108","article-title":"Estimating the association between SF-12 responses and EQ5D utility values by response mapping","volume":"26","author":"Gray","year":"2006","journal-title":"Med Decis Making"},{"key":"10.1016\/j.crohns.2009.11.010_bib18","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/biomet\/78.3.691","article-title":"A note on a general definition of the coefficient of determination","volume":"78","author":"Nagelkerke","year":"1991","journal-title":"Biometrika"},{"key":"10.1016\/j.crohns.2009.11.010_bib19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1477-7525-1-4","article-title":"What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D","volume":"1","author":"Walters","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.crohns.2009.11.010_bib20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/bmj.1.5375.89","article-title":"Variation between observers in describing mucosal appearances in proctocolitis","volume":"1","author":"Baron","year":"1964","journal-title":"Br Med J"},{"key":"10.1016\/j.crohns.2009.11.010_bib21","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000235916","article-title":"Quality of life improvements attributed to combination therapy with oral and topical mesalazine in mild-to-moderately active ulcerative colitis","volume":"80","author":"Connolly","year":"2009","journal-title":"Digestion"},{"key":"10.1016\/j.crohns.2009.11.010_bib22","article-title":"Importance of mucosal healing in ulcerative colitis","author":"Lichtenstein","year":"2009","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.crohns.2009.11.010_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(09)60722-8","article-title":"Identification of items to be included in an Ulcerative Colitis Endoscopic Index of Severity (UCEIS)","volume":"136","author":"Travis","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.11.010_bib24","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0272989X06290495","article-title":"Preference-based EQ-5D index scores for chronic conditions in the United States","volume":"26","author":"Sullivan","year":"2006","journal-title":"Med Decis Making"},{"key":"10.1016\/j.crohns.2009.11.010_bib25","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1524-4733.2007.00181.x","article-title":"Estimation of patient preference-based utility weights from the functional assessment of cancer therapy\u2014general","volume":"10","author":"Dobrez","year":"2007","journal-title":"Value Health"},{"key":"10.1016\/j.crohns.2009.11.010_bib26","series-title":"FAQ: what are pseudo R-squareds?","author":"UCLA Academic Technology Services","year":"2009"},{"key":"10.1016\/j.crohns.2009.11.010_bib27","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/0272989X04265477","article-title":"Mapping the SF-12 to the EuroQol EQ-5D index in a national US sample","volume":"24","author":"Franks","year":"2004","journal-title":"Med Decis Making"},{"key":"10.1016\/j.crohns.2009.11.010_bib28","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/01.mlr.0000172050.67085.4f","article-title":"A national catalog of preference-based scores for chronic conditions in the United States","volume":"43","author":"Sullivan","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.crohns.2009.11.010_bib29","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/00005650-200003000-00006","article-title":"Health Utilities Index Mark 3: evidence of construct validity for stroke and arthritis in a population health survey","volume":"38","author":"Grootendorst","year":"2000","journal-title":"Med Care"},{"issue":"3","key":"10.1016\/j.crohns.2009.11.010_bib30","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/biomet\/78.3.691","article-title":"A note on a general definition of the coefficient of determination","volume":"78","author":"Nagelkerke","year":"1991","journal-title":"Biometrika"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994609001421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994609001421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/4\/3\/275\/1028914\/4-3-275.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T08:42:29Z","timestamp":1558687349000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-lookup\/doi\/10.1016\/j.crohns.2009.11.010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S1873994609001421"],"URL":"https:\/\/doi.org\/10.1016\/j.crohns.2009.11.010","relation":{},"ISSN":["1873-9946"],"issn-type":[{"value":"1873-9946","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}